Suchergebnisse - "Kazandjian, Dickran"

PubPharm (16)

1

Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time

enthalten in: Clinical advances in hematology & oncology : H&O | 2019

von Kazandjian, D. | Landgren, O.

2

Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Sissung, T. | Peer, C. | Korde, N. | +5

3

Characterization of outcomes in patients with metastatic non-small cell lung cancer treated with programmed cell death protein 1 inhibitors past RECIST v1.1-defined disease progression in clinical trials

enthalten in: Seminars in oncology | 2017

von Kazandjian, D. | Keegan, P. | Suzman, D. | +2

4

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2017

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

5

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

enthalten in: Clinical cancer research | 2016

von Kazandjian, D. | Blumenthal, G. | Yuan, W. | +3

6

A Benefit Risk Analysis Approach To Capture Regulatory Decision-Making: Non-Small Cell Lung Cancer

enthalten in: Clinical pharmacology & therapeutics | 2016

von Raju, G. | Gurumurthi, K. | Domike, R. | +4

7

Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone

enthalten in: Leukemia & lymphoma | 2016

von Manasanch, E. | de Larrea, C. | Zingone, A. | +21

8

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

enthalten in: Seminars in oncology | 2016

von Kazandjian, D. | Landgren, O.

9

Flow cytometric sensitivity and characteristics of plasma cells in patients with multiple myeloma or its precursor disease: influence of biopsy site and anticoagulation method

enthalten in: Leukemia & lymphoma | 2015

von Manasanch, E. | Salem, D. | Yuan, C. | +15

10

Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2015

von Blumenthal, G. | Karuri, S. | Zhang, H. | +7